Pulmonary Embolism International THrOmbolysis Study-3
Status:
Not yet recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
In this study, we will assess the efficacy and safety of a reduced dose of thrombolytic
therapy given in addition to low-molecular-weight heparin in patients with
intermediate-high-risk acute pulmonary embolism. Half of participants will receive
thrombolytic treatment, while the other half will receive a placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Boehringer Ingelheim Canadian Institutes of Health Research (CIHR) Johannes Gutenberg University Mainz Life Sciences Research Partners (D Collen Research Foundation) University Medical Center of the Johannes Gutenberg University Mainz, Germany